What is the clinical evidence from this study?

Study design: Review. Population: Vascular insulin resistance. Intervention: Asymmetric Dimethylarginine (ADMA).

September 1, 2008Hormone and Metabolic Research

Asymmetric Dimethylarginine (ADMA) and other Endogenous Nitric Oxide Synthase (NOS) Inhibitors as an Important Cause of Vascular Insulin Resistance

View Full Paper

Ask AI

Bookmark

Key result

Elevated ADMA promotes vascular insulin resistance by uncoupling eNOS and reducing nitric oxide bioavailability.

Why the study?

The role of endogenous NOS inhibitors such as ADMA in vascular insulin resistance and endothelial dysfunction remains unclear and requires further study.

Design

Review

Authors

KTKostas ToutouzasNational and Kapodistrian University of Athens MRMaria RigaDemocritus University of Thrace ESElli StefanadiNational and Kapodistrian University of Athens

Discussion

Member takes

Implication

Should not change clinical practice; leaves open whether L-arginine supplementation improves endothelial outcomes in trials.

PICO

Population

Vascular insulin resistance

Exposure / Comparator

Asymmetric Dimethylarginine (ADMA)

This review highlights the role of ADMA as an endogenous eNOS inhibitor contributing to vascular insulin resistance and endothelial dysfunction, with potential therapeutic implications for L-arginine.

Limitations

It is still difficult to say whether increased ADMA levels in certain populations is only a reason or the result of the molecular alterations, which take place in vascular disease states.
Difficult to determine if increased ADMA levels are a cause or result of molecular alterations in vascular disease states
More studies required to certify the role of NOS inhibitors in insulin resistance and endothelial dysfunction

Cite This Study

Toutouzas et al. (2008) conducted a review in Vascular insulin resistance. Asymmetric Dimethylarginine (ADMA) was evaluated. Elevated asymmetric dimethylarginine (ADMA) levels cause eNOS uncoupling and decreased nitric oxide bioavailability, contributing to vascular insulin resistance.

synapsesocial.com/papers/6aa80837871ca30df5b18684 https://doi.org/10.1055/s-0028-1083814

View Full Paper

Ask AI

Bookmark

Asymmetric Dimethylarginine (ADMA) and other Endogenous Nitric Oxide Synthase (NOS) Inhibitors as an Important Cause of Vascular Insulin Resistance

Discussion

Member takes

Implication

PICO

Limitations

Cite This Study

Asymmetric Dimethylarginine (ADMA) and other Endogenous Nitric Oxide Synthase (NOS) Inhibitors as an Important Cause of Vascular Insulin Resistance

Discussion

Member takes

Implication

PICO

Limitations

Cite This Study

Also Consider

Also Consider